Hand, foot, and mouth disease in children: forecasting of future research direction using bibliometric analysis
Abstract
Since 1997, hand, foot, and mouth disease (HFMD) has become a common health problem in Southeast Asia. Various types of research have been conducted and published to handle HFMD. However, until now, many children, especially in the Asia-Pacific region, including Indonesia, still have HFMD-causing enterovirus (EV) infection. By conducting a bibliometric analysis of the literature published over the last 27 years (1997–2024), the direction of HFMD research in children can be predicted, thus research areas that have the potential and still need to be developed for future better HFMD treatment can be known. The important HFMD research topics predicted to continue to develop were identified through keyword analysis, which was subsequently mapped using a network approach. Based on this study, it can be concluded that HFMD research is predicted to lead to the development of synbiotic supplements, which can reduce HFMD severity, especially in children, by utilizing a genome-wide association study (GWAS) and machine learning.
References
[1] Direktorat Jenderal Pelayanan Kesehatan. “Mengenal penyakit tangan, kaki, dan mulut (flu Singapura),” accessed February 5, 2024. https://yankes.kemkes.go.id/view_artikel/944/mengenal-penyakit-tangan-kaki-dan-mulut-flu-singapura.
[2] Y. Wu, T. Wang, M. Zhao, S. Dong, S. Wang, and J. Shi, “Spatiotemporal cluster patterns of hand, foot, and mouth disease at the province level in Mainland China, 2011–2018,” PLoS One, vol. 17, no. 8, pp. 1–25, 2022.
[3] Y. Xu, Y. Zheng, W. Shi, L. Guan, P. Yu, J. Xu, et al., “Pathogenic characteristics of hand, foot and mouth disease in Shaanxi Province, China, 2010–2016,” Scientific Reports, vol. 10, no. 989, pp. 1–11, 2020.
[4] A. Sharma, V. K. Mahajan, K. S. Mehta, P. S. Chauhan, S. Manvi, and A. Chauhan, “Hand, foot and mouth disease:
a single centre retrospective study of 403 new cases and brief review of relevant Indian literature to understand clinical, epidemiological, and virological attributes of a long-lasting Indian epidemic,” Indian Dermatology Online Journal, vol. 13, no. 3, pp. 310–320, 2022.
[5] X. F. Wang, J. Lu, X. X. Liu, and T. Dai, “Epidemiological features of hand, foot and mouth disease outbreaks
among Chinese preschool children: a meta-analysis,” Iranian Journal of Public Health, vol. 47, no. 9, pp. 1234–1243, 2018.
[6] L. Yi, H. Zeng, H. Zheng, J. Peng, X. Guo, L. Liu, et al., “Molecular surveillance of coxsackievirus A16 in Southern China, 2008–2019,” Archives of Virology, vol. 166, no. 6, pp. 1653–1659, Jun. 2021.
[7] University of Oxford. “Hand, foot and mouth diseases in Indonesia,” accessed February 12, 2024. https://www.research.ox.ac.uk/map/hand-foot-and-mouth-diseases-in-indonesia.
[8] L. Huang, T. Wang, X. Liu, Y. Fu, S. Zhang, Q. Chu, et al., “Spatial–temporal-demographic and virological changes of hand, foot and mouth disease incidence after vaccination in a vulnerable region of China,” BMC Public Health, vol. 22, no. 1468, pp. 1–10, 2022.
[9] J. Wang, L. Jiang, C. Zhang, W. He, Y. Tan, and C. Ning, “The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine,” Vaccine, vol. 39, no. 25, pp. 3319–3323, 2021.
[10] X. Guo, Z. Lan, Y. Wen, C. Zheng, Z. Rong, T. Liu, et al., “Synbiotics supplements lower the risk of hand, foot, and mouth disease in children, potentially by providing resistance to gut microbiota dysbiosis,” Frontiers in Cellular and Infection Microbiology, vol. 11, pp. 1–12, 2021.
[11] C. Shen, Y. Xu, J. Ji, J. Wei, Y. Jiang, Y. Yang, et al., “Intestinal microbiota has important effect on severity of hand foot and mouth disease in children,” BMC Infectious Diseases, vol. 21, no. 1062, pp. 1–16, 2021.
[12] R. Zakaria, A. Ahmi, A. H. Ahmad, Z. Othman, K. F. Azman, C. B. Ab Aziz, et al., “Visualising and mapping a decade of literature on honey research: bibliometric analysis from 2011 to 2020,” Journal of Apicultural Research, vol. 60, no. 3, pp. 359–368, 2021.
[13] CDC. “Centers for Disease Control and Prevention 2021 Child development: preschooler (3-5 years old) | CDC,” accessed February 13, 2024. https://www.cdc.gov/ncbddd/childdevelopment/positiveparenting/preschoolers.html.
[14] S. H. Wei, Y. P. Huang, M. C. Liu, T. P. Tsou, H. C. Lin, T. L. Lin, et al., “An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010,” BMC Infectious Diseases, vol. 11, no. 346, pp. 1–6, 2011.
[15] T. J. Treangen and S. L. Salzberg, “Repetitive DNA and next-generation sequencing: computational challenges and solutions,” Nature Reviews Genetics, vol. 13, no. 1, pp. 36–46, 2011.
[16] F. Syahbanu, P. E. Giriwono, R. R. Tjandrawinata, and M. T. Suhartono, “Molecular analysis of a fibrin-degrading enzyme from Bacillus subtilis K2 isolated from the Indonesian soybean-based fermented food moromi,” Molecular Biology Reports, vol. 47, no. 11, pp. 8553–8563, 2020.
[17] W. T. Ismaya, R. R. Tjandrawinata, and H. Rachmawati, “Lectins from the edible mushroom Agaricus bisporus and their therapeutic potentials,” Molecules, vol. 25, no. 2368, pp. 1–16, 2020.
[18] W. T. Ismaya, R. R. Tjandrawinata, B. W. Dijkstra, J. J. Beintema, N. Nabila, and H. Rachmawati, “Relationship of Agaricus bisporus mannose-binding protein to lectins with β-trefoil fold,” Biochemical and Biophysical Research Communications, vol. 527, no. 4, pp. 1027–1032, 2020.
[19] F. Nailufar, R. R. Tjandrawinata, and M. T. Suhartono, “Thrombus degradation by fibrinolytic enzyme of Stenotrophomonas sp. originated from Indonesian soybean-based fermented food on Wistar rats,” Advances in Pharmacological and Pharmaceutical Sciences, vol. 2016, no. 4206908, pp. 1–9, 2016.
[20] J. Puenpa, A. Theamboonlers, S. Korkong, P. Linsuwanon, C. Thongmee, S. Chatproedprai, et al., “Molecular characterization and complete genome analysis of human enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Thailand during 2008-2011,” Archives of Virology, vol. 156, no. 11, pp. 2007–2013, 2011.
[21] D. Zhang, J. Lu, and J. Lu, “Enterovirus 71 vaccine: close but still far,” International Journal of Infectious Diseases, vol. 14, no. 9, pp. e739–e743, 2010.
[22] C. Yang, C. Deng, J. Wan, L. Zhu, and Q. Leng, “Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications,” Virology Journal, vol. 8, no. 306, pp. 1–6, 2011.
[23] R. R. Tjandrawinata, L. W. Susanto, and D. Nofiarny, “The use of Phyllanthus niruri L. as an immunomodulator for the treatment of infectious diseases in clinical settings,” Asian Pacific Journal of Tropical Disease, vol. 7, no. 3, pp. 132–140, 2017.
[24] R. R. Tjandrawinata, A. W. Amalia, H. Tuna, V. N. Said, and S. Tan, “Molecular mechanisms of network pharmacology-based immunomodulation of huangqi (Astragali Radix),” Jurnal Ilmu Kefarmasian Indonesia, vol. 20, no. 2, pp. 184–195, 2022.
[25] J. Li, J. Yang, X. Fan, Z. Sun, Y. Sun, H. Li, et al., “Genetic analysis of the P1 region of human enterovirus 71 strains and expression of the 55 F strain VP1 protein,” Virologica Sinica, vol. 27, no. 1, pp. 10–18, 2012.
[26] X. Liu, N. Mao, W. Yu, Q. Chai, H. Wang, W. Wang, et al., “Genetic characterization of emerging coxsackievirus A12 associated with hand, foot and mouth disease in Qingdao, China,” Archives of Virology, vol. 159, no. 9, pp. 2497–2502, 2014.
[27] L. Deng, H. L. Jia, C. W. Liu, K. H. Hu, G. Q. Yin, J. W. Ye, et al., “Analysis of differentially expressed proteins involved in hand, foot and mouth disease and normal sera,” Clinical Microbiology and Infection, vol. 18, no. 6, pp. E188–E196, 2012.
[28] J. Hyeon, S. Hwang, H. Kim, J. Song, J. Ahn, B. Kang, et al., “Accuracy of diagnostic methods and surveillance sensitivity for human enterovirus, South Korea, 1999–2011,” Emerging Infectious Diseases, vol. 19, no. 8, pp. 1268–1275, Aug. 2013.
[29] B. Bai, H. Shen, Y. Hu, J. Hou, Z. Liu, R. Li, et al., “Serological survey of a new type of reovirus in humans in China,” Epidemiology and Infection, vol. 142, no. 10, pp. 2155–2158, 2014.
[30] W. Li, L. Yi, J. Su, J. Lu, C. Ke, H. Zeng, et al., “Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period,” PLoS One, vol. 8, no. 12, pp. 1–7, 2013.
[31] J. Liu, P. Huang, Y. He, W. Hong, X. Ren, X. Yang, et al., “Serum amyloid A and clusterin as potential predictive biomarkers for severe hand, foot and mouth disease by 2D-DIGE proteomics analysis,” PLoS One, vol. 9, no. 9, pp. 1–9, 2014.
[32] L. V. Akhmadishina, T. P. Eremeeva, O. E. Trotsenko, O. E. Ivanova, M. I. Mikhailov, and A. N. Lukashev, “Seroepidemiology and molecular epidemiology of enterovirus 71 in Russia,” PLoS One, vol. 9, no. 5, pp. 1–6, 2014.
[33] M. Cabrerizo, D. Tarragó, C. Muñoz-Almagro, E. Amo, M. Domínguez-Gil, J. M. Eiros, et al., “Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain,” Clinical Microbiology and Infection, vol. 20, no. 3, pp. O150–O156, 2014.
[34] P. Linsuwanon, J. Puenpa, S. W. Huang, Y. F. Wang, J. Mauleekoonphairoj, J. R. Wang, et al., “Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations,” Journal of Biomedical Science, vol. 21, no. 1, pp. 1–13, 2014.
[35] Z. Tao, H. Wang, Y. Li, G. Liu, A. Xu, X. Lin, et al., “Molecular epidemiology of human enterovirus associated with aseptic meningitis in Shandong province, China, 2006–2012,” PLoS One, vol. 9, no. 2, pp. 1–10, 2014.
[36] Y. P. Li, Z. L. Liang, Q. Gao, L. R. Huang, Q. Y. Mao, S. Q. Wen, et al., “Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial,” Vaccine, vol. 30, no. 22, pp. 3295–3303, 2012.
[37] Y. P. Li, Z. L. Liang, J. L. Xia, J. Y. Wu, L. Wang, L. F. Song, et al., “Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled trial,” The Journal of Infectious Diseases, vol. 209, no. 1, pp. 46–55, 2014.
[38] R. Li, L. Liu, Z. Mo, X. Wang, J. Xia, Z. Liang, et al., “An inactivated enterovirus 71 vaccine in healthy children,” The New England Journal of Medicine, vol. 370, no. 9, pp. 829–837, 2014.
[39] S. Lu, “EV71 vaccines: a milestone in the history of global vaccine development,” Emerging Microbes & Infections, vol. 3, no. 4, pp. 1–2, 2014.
[40] F. Zhu, W. Xu, J. Xia, Z. Liang, Y. Liu, X. Zhang, et al., “Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China,” The New England Journal of Medicine, vol. 370, no. 9, pp. 818–828, 2014.
[41] Y. Cai, Z. Ku, Q. Liu, Q. Leng, and Z. Huang, “A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses,” Vaccine, vol. 32, no. 21, pp. 2406–2412, 2014.
[42] Z. Ku, Q. Liu, X. Ye, Y. Cai, X. Wang, J. Shi, et al., “A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice,” Vaccine, vol. 32, no. 34, pp. 4296–4303, 2014.
[43] S. Sun, L. Jiang, Z. Liang, Q. Mao, W. Su, H. Zhang, et al., “Evaluation of monovalent and bivalent vaccines against lethal enterovirus 71 and coxsackievirus A16 infection in newborn mice,” Human Vaccines & Immunotherapeutics, vol. 10, no. 10, pp. 2885–2895, 2014.
[44] D. Liu, K. Leung, M. Jit, H. Yu, J. Yang, Q. Liao, et al., “Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease,” Clinical Microbiology and Infection, vol. 26, no. 3, pp. 373–380, 2020.
[45] Y. Lee, Y. Lee, J. Seong, A. Stanescu, and C. S. Hwang, “A comparison of network clustering algorithms in keyword network analysis: a case study with geography conference presentations,” International Journal of Geospatial and Environmental Research, vol. 7, no. 3, pp. 1–14, 2020.
[46] Y. Meng, T. Xiong, R. Zhao, J. Liu, G. Yu, J. Xiao, et al., “Genome-wide association study identifies TPH2 variant as a novel locus for severe CV-A6-associated hand, foot, and mouth disease in Han Chinese,” International Journal of Infectious Diseases, vol. 98, pp. 268–274, 2020.
[47] R. Zou, G. Zhang, S. Li, W. Wang, J. Yuan, J. Li, et al., “A functional polymorphism in IFNAR1 gene is associated
with susceptibility and severity of HFMD with EV71 infection,” Scientific Reports, vol. 5, no. 18541, pp. 1–10, 2015.
[48] Y. Tan, T. Yang, P. Liu, L. Chen, Q. Tian, Y. Guo, et al., “Association of the OAS3 rs1859330 G/A genetic polymorphism with severity of enterovirus-71 infection in Chinese Han children,” Archives of Virology, vol. 162, no. 8, pp. 2305–2313, 2017.
[49] N. Zhao, H. Chen, Z. Chen, J. Li, and Z. Chen, “IL-10-592 polymorphism is associated with IL-10 expression and severity of enterovirus 71 infection in chinese children,” Journal of Clinical Virology, vol. 95, pp. 42–46, 2017.
[50] X. Wang, H. Liu, Y. Li, R. Su, Y. Liu, and K. Qiao, “Relationship between polymorphism of receptor SCARB2 gene and clinical severity of enterovirus-71 associated hand-foot-mouth disease,” Virology Journal, vol. 18, no. 132, pp. 1–10, 2021.
[51] G. P. Chen, K. Xiang, L. Sun, Y. L. Shi, C. Meng, L. Song, et al., “TLR3 polymorphisms are associated with the severity of hand, foot, and mouth disease caused by enterovirus A71 in a Chinese children population,” Journal of Medical Virology, vol. 93, no. 11, pp. 6172–6179, 2021.
[52] M. Li, Y. P. Li, H. L. Deng, M. Q. Wang, Y. Chen, Y. F. Zhang, et al., “DNA methylation and SNP in IFITM3 are correlated with hand, foot and mouth disease caused by enterovirus 71,” International Journal of Infectious Diseases, vol. 105, pp. 199–208, 2021.
[53] G. Liu, Y. Xu, X. Wang, X. Zhuang, H. Liang, Y. Xi, et al., “Developing a machine learning system for identification of severe hand, foot, and mouth disease from electronic medical record data,” Scientific Reports, vol. 7, no. 16341, pp. 1–9, 2017.
[54] Y. Wang, Z. Cao, D. Zeng, X. Wang, and Q. Wang, “Using deep learning to predict the hand-foot-and-mouth disease of enterovirus A71 subtype in Beijing from 2011 to 2018,” Scientific Reports, vol. 10, no. 12201, pp. 1–10, 2020.
[55] B. Zhang, X. Wan, F. Ouyang, Y. D. Hao, D. Luo, J. Liu, et al., “Machine Learning Algorithms for Risk Prediction of Severe Hand-Foot-Mouth Disease in Children,” Scientific Reports, vol. 7, no. 5368, pp. 1–8, 2017.
[56] W. Li, Y. Zhu, Y. Li, M. Shu, Y. Wen, X. Gao, et al., “The gut microbiota of hand, foot and mouth disease patients demonstrates down‐regulated butyrate‐producing bacteria and up‐regulated inflammation‐inducing bacteria,” Acta Paediatrica, vol. 108, no. 6, pp. 1133–1139, 2019.
[57] P. Rahayu, L. Agustina, and R. R. Tjandrawinata, “Tacorin, an extract from Ananas comosus stem, stimulates wound healing by modulating the expression of tumor necrosis factor α, transforming growth factor β and matrix metalloproteinase 2,” FEBS Open Bio, vol. 7, no. 7, pp. 1017–1025, 2017.
[58] P. Rahayu, F. Marcelline, E. Sulistyaningrum, M. T. Suhartono, and R. R. Tjandrawinata, “Potential effect of striatin (DLBS0333), a bioactive protein fraction isolated from Channa striata for wound treatment,” Asian Pacific Journal of Tropical Biomedicine, vol. 6, no. 12, pp. 1001–1007, 2016.
[59] Y. Yuliana, O. M. Tandrasasmita, and R. R. Tjandrawinata, “Anti-inflammatory effect of predimenol, a bioactive extract from Phaleria macrocarpa, through the suppression of NF-κB and COX-2,” Recent Advances in Inflammation & Allergy Drug Discovery, vol. 15, no. 2, pp. 99–107, 2022.
[60] S. Y. Zhu, Y. Z. Jiang, N. Shen, M. Li, H. J. Yin, and J. B. Qiao, “Changes in the intestinal microbiota of children with hand, foot, and mouth disease under 3 years old,” Medicine (Baltimore), vol. 102, no. 18, pp. 1–6, 2023.
[61] Y. Zhuang, Y. Lin, H. Sun, Z. Zhang, T. Wang, R. Fan, et al., “Gut microbiota in children with hand foot and mouth disease on 16S rRNA gene sequencing,” Current Microbiology, vol. 80, no. 159, pp. 1–8, 2023.
[62] R. R. Tjandrawinata, M. Kartawijaya, and A. W. Hartanti, “In vitro evaluation of the anti-hypercholesterolemic effect of Lactobacillus isolates from various sources,” Frontiers in Microbiology, vol. 13, no. 825251, pp. 1–10, 2022.
[63] H. Zhang, L. Zhang, J. Xie, W. Wen, L. Wei, and B. Nie, “Probiotics supplement in children with severe hand, foot, and mouth disease,” Medicine (Baltimore), vol. 98, no. 45, pp. 1–3, 2019.
[2] Y. Wu, T. Wang, M. Zhao, S. Dong, S. Wang, and J. Shi, “Spatiotemporal cluster patterns of hand, foot, and mouth disease at the province level in Mainland China, 2011–2018,” PLoS One, vol. 17, no. 8, pp. 1–25, 2022.
[3] Y. Xu, Y. Zheng, W. Shi, L. Guan, P. Yu, J. Xu, et al., “Pathogenic characteristics of hand, foot and mouth disease in Shaanxi Province, China, 2010–2016,” Scientific Reports, vol. 10, no. 989, pp. 1–11, 2020.
[4] A. Sharma, V. K. Mahajan, K. S. Mehta, P. S. Chauhan, S. Manvi, and A. Chauhan, “Hand, foot and mouth disease:
a single centre retrospective study of 403 new cases and brief review of relevant Indian literature to understand clinical, epidemiological, and virological attributes of a long-lasting Indian epidemic,” Indian Dermatology Online Journal, vol. 13, no. 3, pp. 310–320, 2022.
[5] X. F. Wang, J. Lu, X. X. Liu, and T. Dai, “Epidemiological features of hand, foot and mouth disease outbreaks
among Chinese preschool children: a meta-analysis,” Iranian Journal of Public Health, vol. 47, no. 9, pp. 1234–1243, 2018.
[6] L. Yi, H. Zeng, H. Zheng, J. Peng, X. Guo, L. Liu, et al., “Molecular surveillance of coxsackievirus A16 in Southern China, 2008–2019,” Archives of Virology, vol. 166, no. 6, pp. 1653–1659, Jun. 2021.
[7] University of Oxford. “Hand, foot and mouth diseases in Indonesia,” accessed February 12, 2024. https://www.research.ox.ac.uk/map/hand-foot-and-mouth-diseases-in-indonesia.
[8] L. Huang, T. Wang, X. Liu, Y. Fu, S. Zhang, Q. Chu, et al., “Spatial–temporal-demographic and virological changes of hand, foot and mouth disease incidence after vaccination in a vulnerable region of China,” BMC Public Health, vol. 22, no. 1468, pp. 1–10, 2022.
[9] J. Wang, L. Jiang, C. Zhang, W. He, Y. Tan, and C. Ning, “The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine,” Vaccine, vol. 39, no. 25, pp. 3319–3323, 2021.
[10] X. Guo, Z. Lan, Y. Wen, C. Zheng, Z. Rong, T. Liu, et al., “Synbiotics supplements lower the risk of hand, foot, and mouth disease in children, potentially by providing resistance to gut microbiota dysbiosis,” Frontiers in Cellular and Infection Microbiology, vol. 11, pp. 1–12, 2021.
[11] C. Shen, Y. Xu, J. Ji, J. Wei, Y. Jiang, Y. Yang, et al., “Intestinal microbiota has important effect on severity of hand foot and mouth disease in children,” BMC Infectious Diseases, vol. 21, no. 1062, pp. 1–16, 2021.
[12] R. Zakaria, A. Ahmi, A. H. Ahmad, Z. Othman, K. F. Azman, C. B. Ab Aziz, et al., “Visualising and mapping a decade of literature on honey research: bibliometric analysis from 2011 to 2020,” Journal of Apicultural Research, vol. 60, no. 3, pp. 359–368, 2021.
[13] CDC. “Centers for Disease Control and Prevention 2021 Child development: preschooler (3-5 years old) | CDC,” accessed February 13, 2024. https://www.cdc.gov/ncbddd/childdevelopment/positiveparenting/preschoolers.html.
[14] S. H. Wei, Y. P. Huang, M. C. Liu, T. P. Tsou, H. C. Lin, T. L. Lin, et al., “An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010,” BMC Infectious Diseases, vol. 11, no. 346, pp. 1–6, 2011.
[15] T. J. Treangen and S. L. Salzberg, “Repetitive DNA and next-generation sequencing: computational challenges and solutions,” Nature Reviews Genetics, vol. 13, no. 1, pp. 36–46, 2011.
[16] F. Syahbanu, P. E. Giriwono, R. R. Tjandrawinata, and M. T. Suhartono, “Molecular analysis of a fibrin-degrading enzyme from Bacillus subtilis K2 isolated from the Indonesian soybean-based fermented food moromi,” Molecular Biology Reports, vol. 47, no. 11, pp. 8553–8563, 2020.
[17] W. T. Ismaya, R. R. Tjandrawinata, and H. Rachmawati, “Lectins from the edible mushroom Agaricus bisporus and their therapeutic potentials,” Molecules, vol. 25, no. 2368, pp. 1–16, 2020.
[18] W. T. Ismaya, R. R. Tjandrawinata, B. W. Dijkstra, J. J. Beintema, N. Nabila, and H. Rachmawati, “Relationship of Agaricus bisporus mannose-binding protein to lectins with β-trefoil fold,” Biochemical and Biophysical Research Communications, vol. 527, no. 4, pp. 1027–1032, 2020.
[19] F. Nailufar, R. R. Tjandrawinata, and M. T. Suhartono, “Thrombus degradation by fibrinolytic enzyme of Stenotrophomonas sp. originated from Indonesian soybean-based fermented food on Wistar rats,” Advances in Pharmacological and Pharmaceutical Sciences, vol. 2016, no. 4206908, pp. 1–9, 2016.
[20] J. Puenpa, A. Theamboonlers, S. Korkong, P. Linsuwanon, C. Thongmee, S. Chatproedprai, et al., “Molecular characterization and complete genome analysis of human enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Thailand during 2008-2011,” Archives of Virology, vol. 156, no. 11, pp. 2007–2013, 2011.
[21] D. Zhang, J. Lu, and J. Lu, “Enterovirus 71 vaccine: close but still far,” International Journal of Infectious Diseases, vol. 14, no. 9, pp. e739–e743, 2010.
[22] C. Yang, C. Deng, J. Wan, L. Zhu, and Q. Leng, “Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications,” Virology Journal, vol. 8, no. 306, pp. 1–6, 2011.
[23] R. R. Tjandrawinata, L. W. Susanto, and D. Nofiarny, “The use of Phyllanthus niruri L. as an immunomodulator for the treatment of infectious diseases in clinical settings,” Asian Pacific Journal of Tropical Disease, vol. 7, no. 3, pp. 132–140, 2017.
[24] R. R. Tjandrawinata, A. W. Amalia, H. Tuna, V. N. Said, and S. Tan, “Molecular mechanisms of network pharmacology-based immunomodulation of huangqi (Astragali Radix),” Jurnal Ilmu Kefarmasian Indonesia, vol. 20, no. 2, pp. 184–195, 2022.
[25] J. Li, J. Yang, X. Fan, Z. Sun, Y. Sun, H. Li, et al., “Genetic analysis of the P1 region of human enterovirus 71 strains and expression of the 55 F strain VP1 protein,” Virologica Sinica, vol. 27, no. 1, pp. 10–18, 2012.
[26] X. Liu, N. Mao, W. Yu, Q. Chai, H. Wang, W. Wang, et al., “Genetic characterization of emerging coxsackievirus A12 associated with hand, foot and mouth disease in Qingdao, China,” Archives of Virology, vol. 159, no. 9, pp. 2497–2502, 2014.
[27] L. Deng, H. L. Jia, C. W. Liu, K. H. Hu, G. Q. Yin, J. W. Ye, et al., “Analysis of differentially expressed proteins involved in hand, foot and mouth disease and normal sera,” Clinical Microbiology and Infection, vol. 18, no. 6, pp. E188–E196, 2012.
[28] J. Hyeon, S. Hwang, H. Kim, J. Song, J. Ahn, B. Kang, et al., “Accuracy of diagnostic methods and surveillance sensitivity for human enterovirus, South Korea, 1999–2011,” Emerging Infectious Diseases, vol. 19, no. 8, pp. 1268–1275, Aug. 2013.
[29] B. Bai, H. Shen, Y. Hu, J. Hou, Z. Liu, R. Li, et al., “Serological survey of a new type of reovirus in humans in China,” Epidemiology and Infection, vol. 142, no. 10, pp. 2155–2158, 2014.
[30] W. Li, L. Yi, J. Su, J. Lu, C. Ke, H. Zeng, et al., “Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period,” PLoS One, vol. 8, no. 12, pp. 1–7, 2013.
[31] J. Liu, P. Huang, Y. He, W. Hong, X. Ren, X. Yang, et al., “Serum amyloid A and clusterin as potential predictive biomarkers for severe hand, foot and mouth disease by 2D-DIGE proteomics analysis,” PLoS One, vol. 9, no. 9, pp. 1–9, 2014.
[32] L. V. Akhmadishina, T. P. Eremeeva, O. E. Trotsenko, O. E. Ivanova, M. I. Mikhailov, and A. N. Lukashev, “Seroepidemiology and molecular epidemiology of enterovirus 71 in Russia,” PLoS One, vol. 9, no. 5, pp. 1–6, 2014.
[33] M. Cabrerizo, D. Tarragó, C. Muñoz-Almagro, E. Amo, M. Domínguez-Gil, J. M. Eiros, et al., “Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain,” Clinical Microbiology and Infection, vol. 20, no. 3, pp. O150–O156, 2014.
[34] P. Linsuwanon, J. Puenpa, S. W. Huang, Y. F. Wang, J. Mauleekoonphairoj, J. R. Wang, et al., “Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations,” Journal of Biomedical Science, vol. 21, no. 1, pp. 1–13, 2014.
[35] Z. Tao, H. Wang, Y. Li, G. Liu, A. Xu, X. Lin, et al., “Molecular epidemiology of human enterovirus associated with aseptic meningitis in Shandong province, China, 2006–2012,” PLoS One, vol. 9, no. 2, pp. 1–10, 2014.
[36] Y. P. Li, Z. L. Liang, Q. Gao, L. R. Huang, Q. Y. Mao, S. Q. Wen, et al., “Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial,” Vaccine, vol. 30, no. 22, pp. 3295–3303, 2012.
[37] Y. P. Li, Z. L. Liang, J. L. Xia, J. Y. Wu, L. Wang, L. F. Song, et al., “Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled trial,” The Journal of Infectious Diseases, vol. 209, no. 1, pp. 46–55, 2014.
[38] R. Li, L. Liu, Z. Mo, X. Wang, J. Xia, Z. Liang, et al., “An inactivated enterovirus 71 vaccine in healthy children,” The New England Journal of Medicine, vol. 370, no. 9, pp. 829–837, 2014.
[39] S. Lu, “EV71 vaccines: a milestone in the history of global vaccine development,” Emerging Microbes & Infections, vol. 3, no. 4, pp. 1–2, 2014.
[40] F. Zhu, W. Xu, J. Xia, Z. Liang, Y. Liu, X. Zhang, et al., “Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China,” The New England Journal of Medicine, vol. 370, no. 9, pp. 818–828, 2014.
[41] Y. Cai, Z. Ku, Q. Liu, Q. Leng, and Z. Huang, “A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses,” Vaccine, vol. 32, no. 21, pp. 2406–2412, 2014.
[42] Z. Ku, Q. Liu, X. Ye, Y. Cai, X. Wang, J. Shi, et al., “A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice,” Vaccine, vol. 32, no. 34, pp. 4296–4303, 2014.
[43] S. Sun, L. Jiang, Z. Liang, Q. Mao, W. Su, H. Zhang, et al., “Evaluation of monovalent and bivalent vaccines against lethal enterovirus 71 and coxsackievirus A16 infection in newborn mice,” Human Vaccines & Immunotherapeutics, vol. 10, no. 10, pp. 2885–2895, 2014.
[44] D. Liu, K. Leung, M. Jit, H. Yu, J. Yang, Q. Liao, et al., “Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease,” Clinical Microbiology and Infection, vol. 26, no. 3, pp. 373–380, 2020.
[45] Y. Lee, Y. Lee, J. Seong, A. Stanescu, and C. S. Hwang, “A comparison of network clustering algorithms in keyword network analysis: a case study with geography conference presentations,” International Journal of Geospatial and Environmental Research, vol. 7, no. 3, pp. 1–14, 2020.
[46] Y. Meng, T. Xiong, R. Zhao, J. Liu, G. Yu, J. Xiao, et al., “Genome-wide association study identifies TPH2 variant as a novel locus for severe CV-A6-associated hand, foot, and mouth disease in Han Chinese,” International Journal of Infectious Diseases, vol. 98, pp. 268–274, 2020.
[47] R. Zou, G. Zhang, S. Li, W. Wang, J. Yuan, J. Li, et al., “A functional polymorphism in IFNAR1 gene is associated
with susceptibility and severity of HFMD with EV71 infection,” Scientific Reports, vol. 5, no. 18541, pp. 1–10, 2015.
[48] Y. Tan, T. Yang, P. Liu, L. Chen, Q. Tian, Y. Guo, et al., “Association of the OAS3 rs1859330 G/A genetic polymorphism with severity of enterovirus-71 infection in Chinese Han children,” Archives of Virology, vol. 162, no. 8, pp. 2305–2313, 2017.
[49] N. Zhao, H. Chen, Z. Chen, J. Li, and Z. Chen, “IL-10-592 polymorphism is associated with IL-10 expression and severity of enterovirus 71 infection in chinese children,” Journal of Clinical Virology, vol. 95, pp. 42–46, 2017.
[50] X. Wang, H. Liu, Y. Li, R. Su, Y. Liu, and K. Qiao, “Relationship between polymorphism of receptor SCARB2 gene and clinical severity of enterovirus-71 associated hand-foot-mouth disease,” Virology Journal, vol. 18, no. 132, pp. 1–10, 2021.
[51] G. P. Chen, K. Xiang, L. Sun, Y. L. Shi, C. Meng, L. Song, et al., “TLR3 polymorphisms are associated with the severity of hand, foot, and mouth disease caused by enterovirus A71 in a Chinese children population,” Journal of Medical Virology, vol. 93, no. 11, pp. 6172–6179, 2021.
[52] M. Li, Y. P. Li, H. L. Deng, M. Q. Wang, Y. Chen, Y. F. Zhang, et al., “DNA methylation and SNP in IFITM3 are correlated with hand, foot and mouth disease caused by enterovirus 71,” International Journal of Infectious Diseases, vol. 105, pp. 199–208, 2021.
[53] G. Liu, Y. Xu, X. Wang, X. Zhuang, H. Liang, Y. Xi, et al., “Developing a machine learning system for identification of severe hand, foot, and mouth disease from electronic medical record data,” Scientific Reports, vol. 7, no. 16341, pp. 1–9, 2017.
[54] Y. Wang, Z. Cao, D. Zeng, X. Wang, and Q. Wang, “Using deep learning to predict the hand-foot-and-mouth disease of enterovirus A71 subtype in Beijing from 2011 to 2018,” Scientific Reports, vol. 10, no. 12201, pp. 1–10, 2020.
[55] B. Zhang, X. Wan, F. Ouyang, Y. D. Hao, D. Luo, J. Liu, et al., “Machine Learning Algorithms for Risk Prediction of Severe Hand-Foot-Mouth Disease in Children,” Scientific Reports, vol. 7, no. 5368, pp. 1–8, 2017.
[56] W. Li, Y. Zhu, Y. Li, M. Shu, Y. Wen, X. Gao, et al., “The gut microbiota of hand, foot and mouth disease patients demonstrates down‐regulated butyrate‐producing bacteria and up‐regulated inflammation‐inducing bacteria,” Acta Paediatrica, vol. 108, no. 6, pp. 1133–1139, 2019.
[57] P. Rahayu, L. Agustina, and R. R. Tjandrawinata, “Tacorin, an extract from Ananas comosus stem, stimulates wound healing by modulating the expression of tumor necrosis factor α, transforming growth factor β and matrix metalloproteinase 2,” FEBS Open Bio, vol. 7, no. 7, pp. 1017–1025, 2017.
[58] P. Rahayu, F. Marcelline, E. Sulistyaningrum, M. T. Suhartono, and R. R. Tjandrawinata, “Potential effect of striatin (DLBS0333), a bioactive protein fraction isolated from Channa striata for wound treatment,” Asian Pacific Journal of Tropical Biomedicine, vol. 6, no. 12, pp. 1001–1007, 2016.
[59] Y. Yuliana, O. M. Tandrasasmita, and R. R. Tjandrawinata, “Anti-inflammatory effect of predimenol, a bioactive extract from Phaleria macrocarpa, through the suppression of NF-κB and COX-2,” Recent Advances in Inflammation & Allergy Drug Discovery, vol. 15, no. 2, pp. 99–107, 2022.
[60] S. Y. Zhu, Y. Z. Jiang, N. Shen, M. Li, H. J. Yin, and J. B. Qiao, “Changes in the intestinal microbiota of children with hand, foot, and mouth disease under 3 years old,” Medicine (Baltimore), vol. 102, no. 18, pp. 1–6, 2023.
[61] Y. Zhuang, Y. Lin, H. Sun, Z. Zhang, T. Wang, R. Fan, et al., “Gut microbiota in children with hand foot and mouth disease on 16S rRNA gene sequencing,” Current Microbiology, vol. 80, no. 159, pp. 1–8, 2023.
[62] R. R. Tjandrawinata, M. Kartawijaya, and A. W. Hartanti, “In vitro evaluation of the anti-hypercholesterolemic effect of Lactobacillus isolates from various sources,” Frontiers in Microbiology, vol. 13, no. 825251, pp. 1–10, 2022.
[63] H. Zhang, L. Zhang, J. Xie, W. Wen, L. Wei, and B. Nie, “Probiotics supplement in children with severe hand, foot, and mouth disease,” Medicine (Baltimore), vol. 98, no. 45, pp. 1–3, 2019.
Published
2024-10-31
How to Cite
TAN, Santi; TJANDRAWINATA, Raymond Rubianto.
Hand, foot, and mouth disease in children: forecasting of future research direction using bibliometric analysis.
JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 22, n. 2, p. 261-273, oct. 2024.
ISSN 2614-6495.
Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1563>. Date accessed: 05 nov. 2024.
doi: https://doi.org/10.35814/jifi.v22i2.1563.
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Tools
